Evidence map›Paper›PMID 32185517›Full record

SynthesisJournal of gastroenterology2020

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.

Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho, Suzane Kioko Ono

Registry-linked trialOpen access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05313477 (The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05313477 phase4completednot on this mapstarted 2022, after this paper: background citation

The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate

TypeinterventionalSponsorMahidol UniversityRan2022 to 2023Enrolled64ConditionsParathyroid Hormone, Tenofovir Disoproxil Fumarate, Chronic Hepatitis B Virus, Vitamin DArmsErgocalciferol Capsules, Calcium carbonate
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Immune therapies against chronic hepatitis B.Journal of gastroenterology · 2022
    Review
  14. Review
  15. Access to antiviral therapy for chronic hepatitis B during COVID-19.Revista da Associacao Medica Brasileira (1992) · 2022
    Article
  16. Tenofovir-induced renal and bone toxicity: report of two cases and literature review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Raquel Scherer de FragaDepartment of Gastroenterology, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, São Paulo, SP, 05403-000, Brazil. rschfraga@gmail.com.
Victor Van VaisbergDepartment of Gastroenterology, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, São Paulo, SP, 05403-000, Brazil.
Luiz Cláudio Alfaia MendesDivision of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Flair José CarrilhoDepartment of Gastroenterology, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, São Paulo, SP, 05403-000, Brazil.
Suzane Kioko OnoDepartment of Gastroenterology, University of São Paulo School of Medicine, Av. Dr. Enéas Carvalho de Aguiar, 255 ICHC, 9th floor, Office 9159, São Paulo, SP, 05403-000, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleos(t)ide analogues (NAs) are the main drug category used in chronic hepatitis B (CHB) treatment. Despite the fact that NAs have a favourable safety profile, undesired adverse events (AEs) may occur during the treatment of CHB. Given the eminent number of patients currently receiving NAs, even a small risk of any of these toxicities can represent a major medical issue. The main objective of this review was to analyse information available on AEs associated with the use of NAs in published studies. We choose the following MesH terms for this systematic review: chronic hepatitis B, side effects and treatment. All articles published from 1 January 1990 up to 19 February 2018 in MEDLINE of PubMed, EMBASE, the Cochrane Library and LILACS databases were searched. A total of 120 articles were selected for analysis, comprising 6419 patients treated with lamivudine (LAM), 5947 with entecavir (ETV), 3566 with tenofovir disoproxil fumarate (TDF), 3096 with telbivudine (LdT), 1178 with adefovir dipivoxil (ADV) and 876 with tenofovir alafenamide (TAF). The most common AEs in all NAs assessed were abdominal pain/discomfort, nasopharyngitis/upper respiratory tract infections, fatigue, and headache. TAF displays the highest density of AEs per patient treated among NAs (1.14 AE/treated patient). In conclusion, treatment of CHB with NAs is safe, with a low incidence of AEs. Despite the general understanding TAF being safer than TDF, the number of patients treated with TAF still is too small in comparison to other NAs to consolidate an accurate safety profile. PROSPERO Registration No. CRD42018086471.

Indexed as

Antiviral AgentsHepatitis B, ChronicHumansNucleosidesNucleotidesAntiviral AgentsNucleosidesNucleotidesAdverse eventsChronic hepatitis BNucleotide/nucleoside analogues

Identifiers

PMID32185517
PMCPMC7188775
OpenAlexW3011632156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.